Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has reported Non-Current Assets for 9 consecutive years, with $18.2 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Assets fell 36.77% year-over-year to $18.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.2 million (down 36.77% YoY) and the FY2025 annual result came in at $18.2 million, down 36.77% from the prior year.
• Non-Current Assets declined to $18.2 million in Q4 2025 per IPHA's latest filing, from $31.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for IPHA reached as high as $155.4 million in Q2 2021 and fell as low as $18.2 million in Q4 2025.
• A 5-year average of $72.1 million and a median of $53.8 million in 2023 frame the typical range for Non-Current Assets.
• The largest YoY upside for Non-Current Assets was 3.53% in 2021 against a maximum downside of 99.91% in 2021.
• Year by year, Non-Current Assets stood at $147.1 million in 2021, then plunged by 47.36% to $77.4 million in 2022, then plunged by 60.06% to $30.9 million in 2023, then dropped by 6.84% to $28.8 million in 2024, then slumped by 36.77% to $18.2 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $18.2 million, $31.8 million, and $28.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.